Brain tumour stem cells: Possibilities of new therapeutic strategies

Sara G M Piccirillo, Angelo L. Vescovi

Research output: Contribution to journalArticle

Abstract

Cancers are composed of heterogeneous cell populations, including highly proliferative immature precursors and differentiated cells, which may belong to different lineages. Recent advances in stem cell research have demonstrated the existence of tumour-initiating, cancer stem cells (CSCs) in non-solid and solid tumours. These cells are defined as CSCs because they show functional properties that resemble those of their normal counterpart to a significant extent. This concept applies to CSCs from brain tumours and, particularly, to glioblastoma stem-like cells, which self-renew under clonal conditions and differentiate into neuron- and glia-like cells, and into aberrant cells, with mixed neuronal/astroglia phenotypes. Notably, across serial transplantation into immunodeficient mice, glioblastoma stem-like cells are able to form secondary tumours which are a phenocopy of the human disease. A significant effort is underway to identify both CSC-specific markers and the molecular mechanism that underpin the tumorigenic potential of these cells, for this will have a critical impact on the understanding of the origin of malignant brain tumour and the discovery of new and more specific therapeutic approaches. Lately, the authors have shown that some of the bone morphogenetic proteins can reduce the tumorigenic ability of CSCs in GBMs. This suggests that mechanisms regulating the physiology of normal brain stem cells may be still in place in their cancerous siblings and that this may lead to the development of cures that selectively target the population CSCs found in the patients' tumour mass.

Original languageEnglish
Pages (from-to)1129-1135
Number of pages7
JournalExpert Opinion on Biological Therapy
Volume7
Issue number8
DOIs
Publication statusPublished - Aug 2007

Fingerprint

Neoplastic Stem Cells
Stem cells
Brain Neoplasms
Tumors
Brain
Stem Cells
Neoplasms
Glioblastoma
Therapeutics
Stem Cell Research
Bone Morphogenetic Proteins
Aptitude
Health Services Needs and Demand
Neuroglia
Astrocytes
Brain Stem
Siblings
Physiology
Transplantation
Neurons

Keywords

  • Bone morphogenetic proteins
  • Cancer stem cells
  • Differentiation
  • Glioblastoma multiforme
  • Neural stem cells
  • Tumorigenicity

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Brain tumour stem cells : Possibilities of new therapeutic strategies. / Piccirillo, Sara G M; Vescovi, Angelo L.

In: Expert Opinion on Biological Therapy, Vol. 7, No. 8, 08.2007, p. 1129-1135.

Research output: Contribution to journalArticle

@article{2e15f6e7c4264016b6af81e8df731858,
title = "Brain tumour stem cells: Possibilities of new therapeutic strategies",
abstract = "Cancers are composed of heterogeneous cell populations, including highly proliferative immature precursors and differentiated cells, which may belong to different lineages. Recent advances in stem cell research have demonstrated the existence of tumour-initiating, cancer stem cells (CSCs) in non-solid and solid tumours. These cells are defined as CSCs because they show functional properties that resemble those of their normal counterpart to a significant extent. This concept applies to CSCs from brain tumours and, particularly, to glioblastoma stem-like cells, which self-renew under clonal conditions and differentiate into neuron- and glia-like cells, and into aberrant cells, with mixed neuronal/astroglia phenotypes. Notably, across serial transplantation into immunodeficient mice, glioblastoma stem-like cells are able to form secondary tumours which are a phenocopy of the human disease. A significant effort is underway to identify both CSC-specific markers and the molecular mechanism that underpin the tumorigenic potential of these cells, for this will have a critical impact on the understanding of the origin of malignant brain tumour and the discovery of new and more specific therapeutic approaches. Lately, the authors have shown that some of the bone morphogenetic proteins can reduce the tumorigenic ability of CSCs in GBMs. This suggests that mechanisms regulating the physiology of normal brain stem cells may be still in place in their cancerous siblings and that this may lead to the development of cures that selectively target the population CSCs found in the patients' tumour mass.",
keywords = "Bone morphogenetic proteins, Cancer stem cells, Differentiation, Glioblastoma multiforme, Neural stem cells, Tumorigenicity",
author = "Piccirillo, {Sara G M} and Vescovi, {Angelo L.}",
year = "2007",
month = "8",
doi = "10.1517/14712598.7.8.1129",
language = "English",
volume = "7",
pages = "1129--1135",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - Brain tumour stem cells

T2 - Possibilities of new therapeutic strategies

AU - Piccirillo, Sara G M

AU - Vescovi, Angelo L.

PY - 2007/8

Y1 - 2007/8

N2 - Cancers are composed of heterogeneous cell populations, including highly proliferative immature precursors and differentiated cells, which may belong to different lineages. Recent advances in stem cell research have demonstrated the existence of tumour-initiating, cancer stem cells (CSCs) in non-solid and solid tumours. These cells are defined as CSCs because they show functional properties that resemble those of their normal counterpart to a significant extent. This concept applies to CSCs from brain tumours and, particularly, to glioblastoma stem-like cells, which self-renew under clonal conditions and differentiate into neuron- and glia-like cells, and into aberrant cells, with mixed neuronal/astroglia phenotypes. Notably, across serial transplantation into immunodeficient mice, glioblastoma stem-like cells are able to form secondary tumours which are a phenocopy of the human disease. A significant effort is underway to identify both CSC-specific markers and the molecular mechanism that underpin the tumorigenic potential of these cells, for this will have a critical impact on the understanding of the origin of malignant brain tumour and the discovery of new and more specific therapeutic approaches. Lately, the authors have shown that some of the bone morphogenetic proteins can reduce the tumorigenic ability of CSCs in GBMs. This suggests that mechanisms regulating the physiology of normal brain stem cells may be still in place in their cancerous siblings and that this may lead to the development of cures that selectively target the population CSCs found in the patients' tumour mass.

AB - Cancers are composed of heterogeneous cell populations, including highly proliferative immature precursors and differentiated cells, which may belong to different lineages. Recent advances in stem cell research have demonstrated the existence of tumour-initiating, cancer stem cells (CSCs) in non-solid and solid tumours. These cells are defined as CSCs because they show functional properties that resemble those of their normal counterpart to a significant extent. This concept applies to CSCs from brain tumours and, particularly, to glioblastoma stem-like cells, which self-renew under clonal conditions and differentiate into neuron- and glia-like cells, and into aberrant cells, with mixed neuronal/astroglia phenotypes. Notably, across serial transplantation into immunodeficient mice, glioblastoma stem-like cells are able to form secondary tumours which are a phenocopy of the human disease. A significant effort is underway to identify both CSC-specific markers and the molecular mechanism that underpin the tumorigenic potential of these cells, for this will have a critical impact on the understanding of the origin of malignant brain tumour and the discovery of new and more specific therapeutic approaches. Lately, the authors have shown that some of the bone morphogenetic proteins can reduce the tumorigenic ability of CSCs in GBMs. This suggests that mechanisms regulating the physiology of normal brain stem cells may be still in place in their cancerous siblings and that this may lead to the development of cures that selectively target the population CSCs found in the patients' tumour mass.

KW - Bone morphogenetic proteins

KW - Cancer stem cells

KW - Differentiation

KW - Glioblastoma multiforme

KW - Neural stem cells

KW - Tumorigenicity

UR - http://www.scopus.com/inward/record.url?scp=34548156768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548156768&partnerID=8YFLogxK

U2 - 10.1517/14712598.7.8.1129

DO - 10.1517/14712598.7.8.1129

M3 - Article

C2 - 17696813

AN - SCOPUS:34548156768

VL - 7

SP - 1129

EP - 1135

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 8

ER -